FdaApplication
BLA 103293
Identifiers
- fda_app_no: BLA103293
Properties
| Property | Value |
|---|---|
| applicant_name | Iovance Biotherapeutics Manufacturing LLC |
| application_type | BLA |
| approval_date | 1992-05-05 |
Revenue by product
PROLEUKIN
| Period | Revenue |
|---|---|
| Q2 2026 | $8.6M |
| Q1 2026 | $11.2M |
| Q4 2025 | $21.9M |
| Q3 2025 | $10.0M |
| Q2 2025 | $5.9M |
| Q1 2025 | $5.8M |
| Q4 2024 | $25.0M |
| Q3 2024 | $16.5M |
| Q2 2024 | $18.3M |
| Q1 2024 | $0.7M |
| Q4 2023 | $0.5M |
| Q3 2023 | $0.5M |
| Q2 2023 | $0.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PROLEUKIN | ALDESLEUKIN | 22MILLION INTERNATIONAL UNITS (1.3MG) | For Injection |
1 product